Selumetinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors,
Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations
(A Pediatric MATCH Treatment Trial)
Does the drug selumetinib help stop the growth of cancer in children with cancer?
Basic Study Information
Purpose:Location: University of Rochester
This phase II Pediatric MATCH trial studies how well selumetinib works in treating
with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with MAPK pathway
activation mutations that have spread to other places in the body and have come back
not respond to treatment. Selumetinib may stop the growth of cancer cells by blocking
the enzymes needed for cell growth.
Lead Researcher (Principal Investigator)
Study Contact InformationPhone: (585) 275-5830
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search